Market Overview

ADVENTRX Pharmaceuticals Provides Update on ANX-514


ADVENTRX Pharmaceuticals, Inc. (NYSE: ANX) today provided an update on its product candidate, ANX-514, its polysorbate 80-free formulation of docetaxel.

The U.S. Food and Drug Administration (FDA) determined that ANX-514 could not be approved based on the findings from the bioequivalence study of ANX-514 (Study 514-01) and that additional development activities would be required for approval. ADVENTRX met with the FDA to discuss required activities.

Posted-In: News FDA


Related Articles (ANX)

View Comments and Join the Discussion!

Partner Center